Researchers have used miniature replicas of human nasal tissue to watch rhinoviruses attack, cell by cell, showing that tiny shifts in our local nose immune response can mean the difference between a sniffle and a serious illness.
Cold season’s hidden split: mild misery versus hospital stay
Rhinoviruses are behind a huge share of ordinary colds. They trigger the classic runny nose, scratchy throat and annoying cough that most of us shrug off in a few days.
For some people, though, the same virus can be dangerous. Smokers, people with asthma or chronic obstructive pulmonary disease (COPD), and those with weaker immune systems are more likely to end up struggling to breathe and needing medical care.
Until recently, scientists couldn’t fully explain why the same viral strain behaves almost politely in one person and like a wrecking ball in another.
New work points to a crucial factor: how strongly, and how early, the nose itself switches on its antiviral alarm system.
How scientists built a ‘nose-in-a-dish’
The study team, led by researchers at Yale University, focused on the nasal lining, or epithelium. This is the frontline tissue that rhinoviruses hit when they first enter the body.
They collected nasal epithelial cells from volunteers and grew them in the lab under conditions that mimic the humid, mucus-coated interior of the human nose. Over time, the cells organised into a 3D structure called an organoid.
- Ciliated cells developed tiny hairlike projections that move mucus along.
- Mucus-producing cells formed, secreting the sticky layer that traps germs.
- The surface became exposed to air, like the real nasal passage.
With these “noses-in-a-dish” ready, the scientists infected them with rhinoviruses and used single-cell RNA sequencing, a powerful genetic tool that reveals which genes each individual cell switches on or off during infection.
Interferons: small molecules, big difference
One key player they watched was interferons. These small signalling proteins act as the body’s early-war siren against viruses.
➡️ Inheritance: the new law coming into force in January that changes everything for descendants
➡️ Astronomers confirm the century’s longest eclipse will briefly turn day into night
When a cell senses viral invasion, it releases interferons that warn neighbouring cells and kick-start antiviral defences. Interferons don’t kill viruses directly; they change the state of nearby cells so viruses struggle to copy themselves.
When nasal cells mounted a strong interferon response, only about 1% of them became infected and the virus began to fade within days.
That was a striking result: even without help from the rest of the immune system, a well-primed nasal lining could quietly contain the virus.
When the nasal alarm fails
To see what happens when that alarm system falters, the researchers chemically blocked interferon signalling in their nose organoids and repeated the infection.
This time the picture changed dramatically. Around a third of the cells became infected, and the tissue responded with a storm of inflammatory molecules.
Cytokines, the chemical messengers that help control inflammation, surged. Mucus-related proteins spiked. The normally controlled local defence transformed into something closer to a runaway blaze.
A protein called nuclear factor kappa B (NF-κB) took centre stage in this version of events. NF-κB is a master switch that controls many inflammatory genes.
Without interferons keeping things in check, NF-κB drove an aggressive, over-the-top response that resembles the inflammation seen in severe colds and asthma flare-ups.
Why some people get hit harder
The findings line up with what clinicians see in real life. People who experience very severe symptoms from common respiratory viruses often have problems with interferon responses.
Some have inherited genetic variants that blunt interferon production. Others, such as long-term smokers or people with chronic lung disease, may have noses already inflamed or damaged, making that early, tidy response harder to mount.
In those cases, the body still fights, but the response is delayed and more chaotic. The virus spreads to more cells, NF-κB fires up, and inflammation spirals, leading to wheezing, chest tightness and in some cases hospital admission.
Hunting for smarter antivirals
Armed with a controllable “nose-in-a-dish” model, the research team also tested potential treatments. One focus was rupintrivir, an experimental antiviral that targets a rhinovirus enzyme.
Rupintrivir previously disappointed in clinical trials because it didn’t reduce viral load or speed up recovery enough to justify its use. In the new lab system, though, the drug did something interesting: it dampened the overactive inflammatory response.
That suggests a different role for rupintrivir. Rather than preventing infection outright, it might help vulnerable patients, such as those with COPD, by toning down the damaging immune overreaction in the nose and airways.
Other experts caution that treatments aimed at the immune system must walk a fine line. NF-κB, for example, is involved in many pathways, not just harmful inflammation.
Blunting inflammation too aggressively could leave people less able to clear the virus, or more open to other infections.
What this research means for everyday colds
This work does not suddenly deliver a miracle cure for the common cold. Rhinoviruses are masters of evolution, with dozens of variants that escape immunity and therapies with ease.
What it does offer is a clearer view of where things go wrong in the nose itself, and when. That timing matters. Drugs that boost or mimic interferons might need to be taken very early, ideally at the first hint of symptoms, to give nasal cells a head start before the virus spreads.
Similarly, medicines that gently calm down NF-κB–driven inflammation could be targeted to people at highest risk of severe disease, rather than handed out with every winter sniffle.
Key terms and ideas, explained
| Term | What it means |
|---|---|
| Rhinovirus | A group of viruses that commonly cause colds and can worsen asthma or COPD. |
| Nasal epithelium | The thin sheet of cells lining the inside of the nose, directly exposed to air and germs. |
| Interferons | Alarm molecules released by infected cells that trigger antiviral defences in nearby cells. |
| NF-κB | A protein that controls many genes linked to inflammation and immune responses. |
| Organoid | A lab-grown mini-organ made from human cells that mimics key features of real tissue. |
| Single-cell RNA sequencing | A technique that measures which genes each individual cell is using at a given moment. |
What this might mean for you during cold season
These findings are still in the research stage, but they hint at why some everyday choices and health conditions seem to change how badly a cold hits.
Smoking, for example, can damage the nasal lining and blunt interferon responses, potentially giving viruses easier access. Poor sleep and chronic stress have also been linked with weaker antiviral responses in general, which may intersect with what happens in the nose.
For people with asthma or COPD, this research may pave the way for treatments that protect the nasal epithelium before or during a viral surge. One could imagine inhaled medications that either boost local interferons early or soften excess inflammation later, based on a person’s risk profile.
The work also shows how detailed lab models can reveal nuances that broad clinical trials miss. A drug written off as “ineffective” for reducing virus levels might still be valuable as a way to control damaging inflammation in specific groups.
As more of these nose-in-a-dish systems are built from different types of patients — smokers, children, people with allergies, older adults — researchers will be able to simulate what a cold looks like in many real-world scenarios, without waiting for the next winter wave.
Originally posted 2026-02-21 04:29:59.